Holcomb Kreithen Plastic Surgery & Medspa Completes Acquisition of Coolsculpting Elite Machines
Holcomb Kreithen Plastic Surgery & Medspa Prioritizes Patient Care SARASOTA, FLORIDA, UNITED STATES, May 3, 2021 /EINPresswire.com/ CoolSculpting Elite Machines Shows Holcomb Kreithen Plastic Surgery & Medspa Prioritizes Patient Care.From the first day the doors opened, Holcomb Kreithen Plastic Surgery & Medspa has always placed the needs of the patient first. The acquisition of CoolSculpting Elite Machines is the latest example of this dedication. With access to a novel, non-surgical treatment for the removal of stubborn and unwanted fat deposits, patients will now have access to another treatment option from Holcomb Kreithen Plastic Surgery to help them make their goals come true.
CoolSculpting Elite arrives in the Delaware Valley
Dr. Evan Sorokin, a board-certified plastic surgeon, offers the latest in non-invasive fat reduction to patients in Philadelphia and Southern New Jersey.
News provided by
Share this article
PHILADELPHIA, April 26, 2021 /PRNewswire/
CoolSculpting® is a popular non-invasive fat reduction treatment available throughout the United States, but Delaware Valley residents will have access to the new and improved version thanks to Dr. Evan Sorokin. Patients have loved CoolSculpting for years, and with the upgraded machines, Dr Sorokin s patients can expect faster treatments due to the new, more efficient applicators. In addition, these new applicators treat up to 18% more surface area than previous applicators, making them more powerful and reducing the number of treatment sessions necessary. Dr. Sorokin has acquired two CoolSculpting Elite machines, one for his
- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56
- Delivers Full-Year Net Revenues of $45.804 Billion on a GAAP Basis, an Increase of 37.7 Percent on a Reported Basis; Adjusted Net Revenues Were $45.784 Billion
- Full-Year Global Net Revenues from the Immunology Portfolio Were $22.153 Billion, an Increase of 13.2 Percent on a Reported Basis, or 13.4 Percent on an Operational Basis; U.S. Humira Net Revenues Were $16.112 Billion, an Increase of 8.4 Percent; Internationally, Humira Net Revenues Were $3.720 Billion, a Decrease of 13.6 Percent on a Reported Basis, or 12.5 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.590 Billion; Global Rinvoq Net Revenues Were $731 Million